Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Revvity’s Dual Play: Diagnostics Momentum vs. Biotech Weakness—Will Aggressive Repurchases Drive Impact, Outlook, & Unlock 6 Strategic Catalysts?
Revvity delivered solid Q3 FY24 results, with revenue of $684.25M (+2% organic YoY) and adjusted EPS of $1.28, exceeding estimates by $0.16, supported by an 80-bps expansion in adjusted operating margin to 28.3%. Diagnostics led growth (+5% organic), driven by reproductive health and double-digit gains in newborn screening, reflecting strong demand in China and innovation-led launches like APOE genotyping for Alzheimer’s assessment. Life Sciences showed mixed results, with reagents returning to mid-single-digit growth while instrumentation sales declined in the low teens, weighed by sluggish pharma/biotech capital budgets and delayed Chinese stimulus. Management raised FY24 EPS guidance to $4.83–$4.87 while prudently lowering organic revenue growth to 0–1%, highlighting operational discipline amid near-term challenges. A new $1B share buyback signals confidence in undervaluation and strong free cash flow ($135M in Q3). Key tailwinds include AI-enabled diagnostic solutions, resilient Signals software demand, and anticipated life sciences recovery in 2025, bolstered by Chinese funding flows. Challenges persist in biotech spending and instrumentation delays, but Revvity’s diversified, innovation-driven portfolio provides resilience. The strategic question remains: Can Revvity leverage diagnostics momentum and operational efficiencies to mitigate biotech softness and drive long-term value creation while capitalizing on its aggressive repurchase strategy?